deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02022982

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor PD-0325901 for Patients With KRAS Mutant Non-Small Cell Lung Cancer and Other Solid Tumors

Sponsor: Dana-Farber Cancer Institute

Conditions KRAS Mutant Non-Small Cell Lung Cancer Solid Tumors
Interventions PD-0325901 Palbociclib
Updated 19 times since 2017 Last updated: Mar 18, 2024 Started: Jan 31, 2014 Primary completion: Nov 1, 2017 Completion: Jun 30, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on KRAS Mutant Non-Small Cell Lung Cancer and Solid Tumors, this trial is completed. The trial is conducted by Dana-Farber Cancer Institute and has accumulated 19 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~Nov 2019 · 6 months · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Feb 2022 · 11 months · monthly snapshot~Feb 2022 – ~Feb 2023 · 12 months · monthly snapshot~Feb 2023 – ~Aug 2023 · 6 months · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Mar 2024 · 4 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed · Phase: PHASE1_PHASE2 → PHASE1

  4. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Nov 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 14 earlier versions

  1. Aug 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Feb 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Feb 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Mar 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Mar 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Nov 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. May 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Nov 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  12. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  13. Feb 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations